Human Endogenous Retrovirus K(HML-2) Gag- and Env-Specific T-Cell Responses Are Infrequently Detected in HIV-1-Infected Subjects Using Standard Peptide Matrix-Based Screening R. Brad Jones a , Vivek M. John a , Diana V. Hunter a , Eric Martin a , Shariq Mujib a , Vesna Mihajlovic a , Peter C. Burgers b , Theo M. Luider b , Gabor Gyenes a , Neil C. Sheppard c , Devi SenGupta d , Ravi Tandon d , Feng-Yun Yue a , Erika Benko e , Colin Kovacs e , Douglas F. Nixon d and Mario A. Ostrowski a a Department of Immunology, University of Toronto, Toronto, Ontario, Canada, and the Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Ontario, Canada b Laboratories of Neuro-Oncology/Clinical and Cancer Proteomics, Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands c Vaccine Research, Worldwide Research and Development, Pfizer Inc., San Diego, California, USA d Division of Experimental Medicine, University of California, San Francisco, California, USA e Maple Leaf Medical Clinic, Toronto, Ontario, Canada ABSTRACT T-cell responses to human endogenous retrovirus (HERV) K(HML-2) Gag and Env were mapped in HIV-1-infected subjects using 15mer peptides. Small peptide pools and high concentrations were used to maximize sensitivity. In the 23 subjects studied, only three bona fide HERV-K(HML-2)-specific responses were detected. At these high peptide concentrations, we detected false-positive responses, three of which were mapped to an HIV-1 Gag peptide contaminant. Thus, HERV-K(HML-2) Gag- and Env-specific T-cell responses are infrequently detected by 15mer peptide mapping.
Human Endogenous Retrovirus K(HML-2) Gag- and Env-Specific T-Cell Responses Are Infrequently Detected in HIV-1-Infected Subjects Using Standard Peptide Matrix-Based Screening
Abstract
Human Endogenous Retrovirus K(HML-2) Gag- and Env-Specific T-Cell Responses Are Infrequently Detected in HIV-1-Infected Subjects Using Standard Peptide Matrix-Based Screening R. Brad Jones a , Vivek M. John a , Diana V. Hunter a , Eric Martin a , Shariq Mujib a , Vesna Mihajlovic a , Peter C. Burgers b , Theo M. Luider b , Gabor Gyenes a , Neil C. Sheppard c , Devi SenGupta d , Ravi Tandon d , Feng-Yun Yue a , Erika Benko e , Colin Kovacs e , Douglas F. Nixon d and Mario A. Ostrowski a a Department of Immunology, University of Toronto, Toronto, Ontario, Canada, and the Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Ontario, Canada b Laboratories of Neuro-Oncology/Clinical and Cancer Proteomics, Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands c Vaccine Research, Worldwide Research and Development, Pfizer Inc., San Diego, California, USA d Division of Experimental Medicine, University of California, San Francisco, California, USA e Maple Leaf Medical Clinic, Toronto, Ontario, Canada ABSTRACT T-cell responses to human endogenous retrovirus (HERV) K(HML-2) Gag and Env were mapped in HIV-1-infected subjects using 15mer peptides. Small peptide pools and high concentrations were used to maximize sensitivity. In the 23 subjects studied, only three bona fide HERV-K(HML-2)-specific responses were detected. At these high peptide concentrations, we detected false-positive responses, three of which were mapped to an HIV-1 Gag peptide contaminant. Thus, HERV-K(HML-2) Gag- and Env-specific T-cell responses are infrequently detected by 15mer peptide mapping.Preview Only. This article cannot be rented because we do not currently have permission from the publisher.
/lp/american-society-for-microbiology/human-endogenous-retrovirus-k-hml-2-gag-and-env-specific-t-cell-rd37nhhtf0
Welcome to DeepDyve! Rent Premier Research Articles and Save Up to 90%
Preview Only
Human Endogenous Retrovirus K(HML-2) Gag- and Env-Specific T-Cell Responses Are Infrequently Detected in HIV-1-Infected Subjects Using Standard Peptide Matrix-Based Screening
Jones, R. Brad; John, Vivek M.; Hunter, Diana V.; Martin, Eric; Mujib, Shariq; Mihajlovic, Vesna; Burgers, Peter C.; Luider, Theo M.; Gyenes, Gabor; Sheppard, Neil C.; SenGupta, Devi; Tandon, Ravi; Yue, Feng-Yun; Benko, Erika; Kovacs, Colin; Nixon, Douglas F.; Ostrowski, Mario A.
Follow Clinical and Vaccine Immunology
, Volume 19 (2): 288
American Society For Microbiology – Feb 1, 2012
More Info
More Like This Article
View All dataSource[]=actageo&dataSource[]=aspet&dataSource[]=aaos&dataSource[]=aacc&dataSource[]=aacr&dataSource[]=aea&dataSource[]=aip&dataSource[]=ajnr&dataSource[]=ams&dataSource[]=aps_physical&dataSource[]=appi_book&dataSource[]=appi_journal&dataSource[]=apha&dataSource[]=asip&dataSource[]=asm&dataSource[]=asn&dataSource[]=aspb&dataSource[]=avs&dataSource[]=annual_reviews&dataSource[]=arxiv&dataSource[]=acm&dataSource[]=berghahn&dataSource[]=cabi&dataSource[]=clinical_trials&dataSource[]=dailymed&dataSource[]=degruyter&dataSource[]=du_press&dataSource[]=esa&dataSource[]=eu_press&dataSource[]=elsevier&dataSource[]=emerald&dataSource[]=ejtr&dataSource[]=emea&dataSource[]=epo&dataSource[]=faseb&dataSource[]=gsa&dataSource[]=health_affairs&dataSource[]=hindawi&dataSource[]=imanager&dataSource[]=imedpub&dataSource[]=informa_healthcare&dataSource[]=informs&dataSource[]=iop&dataSource[]=iucr&dataSource[]=iospress&dataSource[]=jbjs&dataSource[]=leftcoast&dataSource[]=lu_press&dataSource[]=mesharpe&dataSource[]=mary_ann_liebert&dataSource[]=medline&dataSource[]=mit_press&dataSource[]=nature&dataSource[]=oxford&dataSource[]=pier_professional&dataSource[]=pnas&dataSource[]=portlandpress&dataSource[]=psyc_articles&dataSource[]=psyc_books&dataSource[]=psyc_critiques&dataSource[]=plos_journal&dataSource[]=pubmed_central&dataSource[]=rsna&dataSource[]=rockefeller&dataSource[]=rcn&dataSource[]=ria&dataSource[]=rsc&dataSource[]=sage&dataSource[]=spie&dataSource[]=springer_journal&dataSource[]=springer&dataSource[]=taylor_francis&dataSource[]=aps&dataSource[]=the_scientist&dataSource[]=uc_press&dataSource[]=uspto_abstract&dataSource[]=wiley&dataSource[]=pct
© 2012 DeepDyve, Inc. All rights reserved.
Terms of Service | Privacy Policy
